CKD32021

Call for Papers

Overcome the translational challenges limiting the development of the next generation of CKD therapeutics. For the 3rd year, the Chronic Kidney Disease Drug Development Summit (CKD3) is putting the hottest topics in CKD drug development under the spotlight. Addressing questions including: what are the mechanisms driving the beneficial effects in SGLT2 inhibition, how is pharma harnessing the power of AI and what kidney organoids are providing innovation to target identification: CKD3 is the definitive, intimately focused forum promoting cross stakeholder discussion and networking to accelerate the next line of CKD drugs. Built with insight from 30+ kidney heavy weights including Reata Pharmaceuticals, AstraZeneca, Goldfinch Bio and Boehringer Ingelheim, the 3rd CKD3 Summit will comprehensively analyze the challenges in CKD drug development from genetics to costing, providing the thought-leading synthesis of all the information you need to accelerate meaningful therapeutics to renal disease patients.

Prices: 

Conference + Workshop Day - Industry Pricing: USD 2720.0, 

Conference Only - Industry Pricing: USD 2169.0, 

Workshop Day Only - Industry Pricing: USD 651.0, 

Conference + Workshop Day - Biotech and Academic Pricing: USD 1719.0, 

Conference only - Biotech and Academic Pricing: USD 1399.0, 

Workshop Day Only - Biotech and Academic Pricing: USD 420.0

Speakers: Andrew King, Head of Renal Discovery and Translational Medicine, Chinook Therapeutics, Beno Freedman, Assistant Professor, Nephrology, University of Washington, Dorothee Oberdhan, Associate Director, Health Outcomes, Otsuka Pharmaceuticals, Frank Czerwiec, Chief Medical Officer, Goldfinch Bio , Fredrik Erlandsson, Global Clinical Lead for Verinurad, AstraZeneca , Harry Alcorn, Chief Medical Officer, Diamedica, Hitesh Soni, Renal Fibrosis Gene Therapy Lead Renascent, Biosciences, Jeremy Duffield, Global Head of Human Biology, Vertex Pharmaceuticals, Jonathan Himmelfarb, Director of the Kidney Research Institute and Professor of Medicine, University of Washington, Joseph Stavas, Senior Vice President, Clinical Development, inRegen, Josh Tarnoff, Chief Executive Officer, NephCure International, Jyothis George, Vice President, Clinical, Medical and Regulatory, Novo Nordisk, Kevin Fowler, President, The Voice of the Patient, Liron Walsh, Vice President of Translational and Clinical Nephrology, Goldfinch Bio, Matt Breyer, Distinguished Scientist, Janssen, Matt Devalaraja, Executive Vice President, Head of Research and Development, Corvidia Therapeutics, Matthias Kretzler, Professor of Medicine Nephrology/ Internal Medicine and Bioinformatics, University of Michigan, Nick LaBella, Chief Scientific Officer, ZyVersa Therapeutics, Pernille Hansen, Senior Director and Head of Bioscience, AstraZeneca, Ravi Kumar, Senior Vice President and Chief Scientific Officer, Acceleron Pharma, Ron Perrone, Scientific Director, Clinical and Translational Research Center; Professor Tufts, University School of Medicine, Scott MacDonnell, Associate Director, Cardiovascular and Fibrosis Research, Regeneron Pharmaceuticals, Tzu-Ling (Karen) Tseng, Chief Executive Officer, Bio Preventive Medicine Corp, Uptal Patel, Executive Director, Clinical Research, Gilead , Vishal Vaidya, Translational Omics Group Head, Pfizer, Wenjun Ju, Associate Research Scientist of Internal Medicine, University of Michigan, Aliza Thompson, Clinical Team Leader, Division of Cardiovascular and Renal Products, FDA, Anjali Pandey, SVP of Nonclinical R and D and Chemistry, twoXAR Pharmaceuticals, Colin Meyer, Chief Research and Development Officer, Reata Pharmaceuticals, Maria Chiara, Magnone Vice President Kidney Diseases and Boston Site Head, Janssen R and D, Richard Nkulikiyinka, VP, Head of Therapeutic Area Cardiology and Nephrology, Bayer Pharmaceuticals, Robert Edwards, Clinical Project Scientist, Janssen Pharmaceuticals, Sibylle Hauske, Senior Medical Director and Global Clinical Development Lead - Empagliflozin in CKD, Boehringer Ingelheim, Yshai Yavin, Director, Cardiovascular and Metabolism Development, Janssen Pharmaceuticals

Time: 10:00 - 17:00